Analy Meth Dev

8/2/2019 Analy Meth Dev

1/51

Birgit Schmauser | April 20081 |

Pharmaceutical Development with Focus

on Paediatric formulations

Pharmaceutical Development with Focus

on Paediatric formulations

WHO/FIP Training Workshop

Hyatt Regency Hotel

Sahar Airport Road

Andheri East, Mumbai, India

28 April 2008 2 May 2008


2/51


Analytical Method DevelopmentAnalytical Method Development

Presented by:Presented by:

Birgit Schmauser, PhDBirgit Schmauser, PhD

Federal Institute for DrugsFederal Institute for Drugs

and Medical Devices (BfArM)and Medical Devices (BfArM)

[email protected]@bfarm.de
http://www.travelphoto.net/photos/pictures/indien/in10.jpg


3/51



In this presentation:In this presentation:

Standards in developing analytical methods forStandards in developing analytical methods for

Originator and multisource generic FPPsOriginator and multisource generic FPPs

SpecificationsSpecifications

StabilityStability

Parallel development of analytical methods forParallel development of analytical methods for

cleaning validationcleaning validation


4/51



OriginatorOriginator,, First-timeFirst-time GenericGeneric and Multisource Genericand Multisource GenericOriginatorOriginator First-timeFirst-time GenericGeneric Multisource GenericMultisource Generic

API qualityAPI qualitystandardsstandards

OriginatorsOriginatorsspecificationsspecifications

Information fromInformation fromregulatory agenciesregulatory agencies(publicly available) &(publicly available) &

literature dataliterature data

PharmacopoeiasPharmacopoeias

FPP qualityFPP qualitystandardsstandards

OriginatorsOriginatorsspecificationsspecifications

Information fromInformation fromregulatory agenciesregulatory agencies(publicly available) &(publicly available) &literature dataliterature data

PharmacopoeiasPharmacopoeias

AnalyticalAnalytical

methodsmethods

EstablishEstablish identity,identity,

potency, purity of APIpotency, purity of APIand FPP byand FPP byin-house methodsin-house methods

DeriveDerive identity, potency,identity, potency,

purity of API and FPP bypurity of API and FPP byin house methodsin house methods

VerifyVerify identity, potency,identity, potency,

purity of API and FPP bypurity of API and FPP bypharmacopoeial methodspharmacopoeial methodsand in-house methodsand in-house methods


5/51



HPLC-method to assay potency and purity risk assessmentHPLC-method to assay potency and purity risk assessmentOriginatorOriginator First-timeFirst-time GenericGeneric Multisource GenericMultisource Generic

SelectivelySelectively screenscreen/detect any/detect anyimpurity or degradantimpurity or degradantEstablishEstablish potencypotency

IdentifyIdentify impurities/degradantsimpurities/degradants

CharacteriseCharacterise allallimpurities/degradantsimp

urities/degradants CalculateCalculateResponse factorsResponse factors(qualification by clinical use)(qualification by clinical use)

DeriveDerive impurities/degradants fromimpurities/degradants fromOriginatorOriginatorCharacterize in-houseCharacterize in-houseimpurities/degradantsimpurities/degradantsCalculate response factorsCalculate response factors

Verify impurities fromVerify impurities fromPharmacopoeiaPharmacopoeiaCharacterise in-houseCharacterise in-houseimpurities/degradantsimpurities/degradants(Response factors)(Response factors)

EstablishEstablish reference materialsreference materials ExtractExtract (&(& reproducereproduce) reference) referencematerialsmaterials

Use pharmacopoeial referenceUse pharmacopoeial referencematerialsmaterials

AdaptAdapt to routine useto routine use AdaptAdapt/modify to/for routine use/modify to/for routine use Implement for routine useImplement for routine use


6/51



Interchangeability (IC) ofInterchangeability (IC) ofmultisource generic FPPsmultisource generic FPPs((Essential similarityEssential similarity with Innovator FPP)with Innovator FPP)

PharmaceuticalPharmaceutical ++ BioequivalenceBioequivalenceEquivalenceEquivalence

IC =IC = PEPE ++ BEBE


7/51



Pharmaceutical equivalencePharmaceutical equivalence FPPs meet theFPPs meet the samesame ororcomparablecomparable standardsstandards byby

use of equivalent analytical methodsuse of eq

uivalent analytical methods

SameSame APIAPI ((chemicalchemical andand physicalphysical

equivalence)equivalence) SameSame dosage formdosage form andand route ofroute of

administrationadministration

SameSame strengthstrength

ComparableComparable labelinglabeling Equivalence inEquivalence in pharmaceutical developmentpharmaceutical development

Equivalence inEquivalence in stabilitystability

Equivalence inEquivalence in manufacture (WHO-GMP)manufacture (WHO-GMP)


8/51Birgit Schmauser | April 20088 |


Prequalification requirementsPrequalification requirements Validation of analytical methods is aValidation of analytical methods is a prerequisiteprerequisite forfor

prequalification of product dossiersprequalification of product dossiers

Non-compendial APIs and FPPsNon-compendial APIs and FPPs are tested withare tested with methodsmethodsdeveloped by the manufacturerdeveloped by the manufacturer

ForFor compendial APIs and FPPs the applicability ofcompendial APIs and FPPs the applicability ofpharmacopoeial methodspharmacopoeial methods to particular productsto particular products mustmust

be demonstrated (verification)be demonstrated (verification)

Analytical methods must be developed and validatedAnalytical methods must be developed and validated

according to TRS 823,according to TRS 823, Annex 5,Annex 5, Validation of analyticalValidation of analytical

procedures used in the examination of pharmaceuticalprocedures used in the examination of pharmaceuticalmaterialsmaterials; ICH Q2 (R1); ICH Q2 (R1)

To be used within GLP and GMP environmentsTo be used within GLP and GMP environments


9/51Birgit Schmauser | April 20089 |


CLINICALCLINICAL PHARMACEUTICALPHARMACEUTICAL METHODSMETHODS

AtAt initialinitial phase of pharmaceutical developmentphase of pharmaceutical development

ToTo determinedeterminebioavailabilitybioavailability in healthyin healthyvolunteersvolunteers

To develop a stable andTo develop a stable andreproducible formulation for thereproducible formulation for themanufacture of bioequivalence,manufacture of bioequivalence,

dissolution, stability and pilot-dissolution, stability and pilot-scale validation batchesscale validation batches

To understand theTo understand the profileprofile of relatedof relatedsubstances and to studysubstances and to study stabilitystability

To startTo start measuringmeasuring the impact ofthe impact ofkeykey

productproduct andand manufacturing processmanufacturing processparametersparameters onon consistentconsistent FPP qualityFPP quality

AtAt advancedadvanced phase of pharmaceutical developmentphase of pharmaceutical development

To proveTo prove bioequivalencebioequivalenceafteraftercritical variationscritical variations totothe prequalified dossierthe prequalified dossier

ToTo optimiseoptimise,, scale-upscale-up andand transfertransferaa stablestable andand controlledcontrolledmanufacturing process for themanufacturing process for theprequalification productprequalification product

To beTo be robust, transferable, accuraterobust, transferable, accurateandand preciseprecise for specification setting,for specification setting,stability assessment and QC release ofstability assessment and QC release ofprequalified product batchesprequalified product batches

Use of analytical methods -Use of analytical methods - genericsgenerics


10/51



PrerequisitesPrerequisites for analytical method validationfor analytical method validation Six Ms

Quality of theQuality of the

analytical methodanalytical method

MManan MMachineachine

qualifiedqualified

calibratedcalibrated

robustrobust

qualifiedqualified

MMethodsethods

suitablesuitable

characterisedcharacterised

documenteddocumented

MMilieuilieuMMaterialaterial MManagementanagement

QualityQuality

ReferenceReference

standardsstandards

Tempe-Tempe-raturerature

AnalystsAnalysts

supportsupport

skilledskilled

HumidityHumidity

VibrationsVibrations TimeTime

SuppliesSupplies

Irradi-Irradi-

ationsations


11/51



Method development life cycleMethod development life cycle

Planning

Development and Validation Policy

Objectives/Requirements of Method

Information GatheringResource Gathering

Method developmentInitital Method Development

Pre-Validation Evaluation

Method Optimization

Robustness

System Suitability

Development

Plan

Project

Customer Evaluation

TestingValidation Experiments

Method Transfer

ExperimentsFiled Method in Use

Periodically

Monitoring/Reviewof Methods

in Control LabsFrom: Analytical Chemistry in a GMP Environment. Edited by J.M. Miller and J.B. Crowther, ISBN 0-471-31431-5, Wiley & Sons IncFrom: Analytical Chemistry in a GMP Environment. Edited by J.M. Miller and J.B. Crowther, ISBN 0-471-31431-5, Wiley & Sons Inc..


12/51



Validation should verify the suitability of anValidation should verify the suitability of ananalytical methodanalytical method for its intended purposefor its intended purpose

Validation should be founded onValidation should be founded on methodmethod

development performed beforehanddevelopment performed beforehand thatthatsuggest thesuggest the suitability and robustnesssuitability and robustness of theof themethodmethod

Validation may be performed in different waysValidation may be performed in different ways(individual purpose) according to(individual purpose) according to commoncommonstandardsstandards


13/51


Validation protocolValidation protocol Method principle / objectiveMethod principle / objective

Listing of responsibilitiesListing of responsibilities

Laboratories involved and their role in the validationLaboratories involved and their role in the validation

Method categorizationMethod categorization

List of reagents (including test lots) and standardsList of reagents (including test lots) and standards

Test procedures to evaluate each validation parameter and proposedTest procedures to evaluate each validation parameter and proposedacceptance criteriaacceptance criteria

Plan or procedure when acceptance criteria are not metPlan or procedure when acceptance criteria are not met

Requirements for the final reportRequirements for the final report

The validation process cannot proceed until the protocol and allThe validation process cannot proceed until the protocol and allparties involved approve the acceptance criteriaparties involved approve the acceptance criteria


14/51



Innovator versus GenericsInnovator versus Generics

InnovatorInnovator GenericsGenerics

R & D on APIR & D on API ++ --

Preclinical trialsPreclinical trials ++ --

Clinical trials phase I and IIClinical trials phase I and II Method validationMethod validation

summarysummary--

Clinical trials phase IIIClinical trials phase III Method validationMethod validationcompletedcompleted

--

Post marketing phase IVPost marketing phase IV Validated methodsValidated methods --

Entering of Generics; PharmaceuticalEntering of Generics; Pharmaceutical

development, Comparability withdevelopment, Comparability withInnovatorInnovator

Validated methodsValidated methods Validated methods:Validated methods:

GMP and GLPGMP and GLP


15/51



Validation CharacteristicsValidation CharacteristicsIdentificationIdentification ImpuritiesImpurities AssayAssay

quantitativequantitative limitlimit

AccuracyAccuracy -- ++ -- ++

PrecisionPrecision -- ++ -- ++SpecificitySpecificity ++ ++ ++ ++

Detection LimitDetection Limit -- -- ++ --

Quantitation LimitQuantitation Limit -- ++ -- --

LinearityLinearity -- ++ -- ++

RangeRange -- ++ -- ++

RobustnessRobustness ++ ++ ++ ++


16/51



Accuracy and precisionAccuracy and precision

Accurate &Accurate &

preciseprecise Accurate &Accurate &impreciseimprecise

InaccurateInaccurate&&

preciseprecise Inaccurate & impreciseInaccurate & imprecise


17/51



PrecisionPrecision Expresses theExpresses the closeness of agreementcloseness of agreement between a series ofbetween a series of

measurements obtained from multiple sampling of the samemeasurements obtained from multiple sampling of the same

homogenous samplehomogenous sample

Is usually expressed as theIs usually expressed as the standard deviation (S),standard deviation (S), variancevariance (S(S22))

ororcoefficient of variationcoefficient of variation (RSD)(RSD) of a series of measurementsof a series of measurements

Precision may be considered at three levelsPrecision may be considered at three levels

RepeatabilityRepeatability(intra-assay precision)(intra-assay precision)

Intermediate PrecisionIntermediate Precision(variability within a(variability within a

laboratory)laboratory) ReproducibilityReproducibility(precision between laboratories)(precision between laboratories)


18/51



Normal distribution,Normal distribution, probability function [P(x)]probability function [P(x)]

and confidence interval [CI]and confidence interval [CI] Probability (P)Probability (P), that measurements from a normal distribution fall within [-x, that measurements from a normal distribution fall within [-xnn, +x, +xnn]]

for xfor xnn = n= n is described by theis described by the erferf-function-function ((= mean)mean):

An interval of 3An interval of 3 coverscovers 99.73% of values99.73% of values

Numberoftimeseachvalue

occursxxnn PP

0.68268950.6826895

22 0.95449970.9544997

33 0.99730020.9973002

44 0.99993660.9999366

55 0.99999940.9999994

Values23 2 3


19/51



Normal distribution, probability function [P(x)] andNormal distribution, probability function [P(x)] and

confidenceconfidence

interval [CI]interval [CI]

Probability-PProbability-P Confidence interval [CI]Confidence interval [CI]

centered around the mean []centered around the mean []

in units of sigma [in units of sigma [] described by] described byinverseinverse erferf-function:-function:

A CI of 95% includes valuesA CI of 95% includes values

1.95 1.95 around the meanaround the mean

PP xxpp

0.8000.800 1.281551.28155

0.9000.900 1.644851.64485

0.9500.950 1.959961.95996

0.9950.995 2.575832.57583

0.9990.999 3.290533.29053


20/51



Relationship of variability, probability and reliability of dataRelationship of variability, probability and reliability of data High variability of data (largeHigh variability of data (large ) generate large confidence intervals and) generate large confidence intervals and

thus lower the reliability of the meanthus lower the reliability of the mean

Low variability of data (smallLow variability of data (small )) generate small confidence intervals andgenerate small confidence intervals andthus increase the reliability of the meanthus increase the reliability of the mean


21/51



RepeatabilityRepeatability Six replicate sample preparation steps from a homogenously prepared tabletSix replicate sample preparation steps from a homogenously prepared tablet

mixture (nominal value of API 150 mg)mixture (nominal value of API 150 mg)

InjectionInjection Peak areaPeak area AssayAssay

11 173865173865 147.10 mg/98.06%147.10 mg/98.06%

22 174926174926 148.00 mg/98.66%148.00 mg/98.66%

33 172933172933 146.32 mg/97.54%146.32 mg/97.54%

44 175011175011 148.08 mg/98.72%148.08 mg/98.72%

55 179557179557 151.95 mg/101.30%151.95 mg/101.30%

66 176425176425 149.28 mg/99.52%149.28 mg/99.52%

MeanMean 175453175453 148.45 mg/98.96%148.45 mg/98.96%

SD (SD ()) 23292329 1.98 mg/1.32%1.98 mg/1.32%

RSDRSD 1.32%1.32% 1.32%1.32%

MeanMean 3 SD = 3 SD =Confidence interval of 99.73%Confidence interval of 99.73%

98.9698.963x1.32% =3x1.32% = 95%95% - 102.92%- 102.92%


22/51



Intermediate precisionIntermediate precision Expresses within-laboratories variations (different days, different analysts,Expresses within-laboratories variations (different days, different analysts,

different equipment etc.)different equipment etc.)

InjectionInjection Peak areaPeak areaanalyst 1analyst 1

Peak areaPeak areaanalyst 2analyst 2

Peak areaPeak areaanalyst 3analyst 3

11 173865173865 175656175656 17796517796522 174926174926 175878175878 178556178556

33 172933172933 176004176004 177342177342

44 175011175011 176344176344 178011178011

55 179557179557 175332175332 179466179466

66 176425176425 174959174959 179688179688

MeanMean 175453175453 175695175695 178504178504SD (SD ()) 23292329 495495 918918

RSDRSD 1.32%1.32% 0.28%0.28% 0.51%0.51%

Analyst 1: 98.96%Analyst 1: 98.96% 3 x 1.32% 3 x 1.32%

Analyst 2: 99.12%Analyst 2: 99.12% 3 x 0.28 3 x 0.28

Analyst 3: 100.70%Analyst 3: 100.70% 3 x 0.51 3 x 0.51

Average of 3 analystsAverage of 3 analysts 3SD 3SD::

95%95% - 102.23%- 102.23%

MeanMean 3 SD: (177252 3 SD: (177252

100%100%))


23/51



ReproducibilityReproducibility

Expresses the precision between laboratoriesExpresses the precision between laboratories

Collaborative studies, usually applied toCollaborative studies, usually applied to

standardisation of methodologystandardisation of methodology

Transfer of technologyTransfer of technology

Compendial methodsCompendial methods


24/51



AccuracyAccuracy Expresses theExpresses the closeness of agreementcloseness of agreement betweenbetween the value which isthe value which is

accepted either as a conventionalaccepted either as a conventional true valuetrue value ororan acceptedan accepted

reference valuereference value and theand the value foundvalue found

Sometimes referred to as Sometimes referred to as TRUENESSTRUENESS

truetruemeanmean


25/51



To find out whether a method is accurate:To find out whether a method is accurate: Drug substance (assay)Drug substance (assay)

Application of the method to an analyte of known purity (e.g. referenceApplication of the method to an analyte of known purity (e.g. referencesubstance)substance)

Comparison of the results of one method with those of a second well-Comparison of the results of one method with those of a second well-

characterised method (accuracy known)characterised method (accuracy known)

Drug product (assay)Drug product (assay) Application of the method to synthetic mixtures of the drug product componentApplication of the method to synthetic mixtures of the drug product component

to whichto which known quantitiesknown quantities of the analyte have been addedof the analyte have been added

Drug product may exceptionally be used as matrixDrug product may exceptionally be used as matrix

Drug substance/Drug product (Impurities)Drug substance/Drug product (Impurities) Application of the method to samples spiked withApplication of the method to samples spiked with known amountsknown amounts of impuritiesof impurities


26/51



AccuracyAccuracy:: Application of the method to synthetic mixtures of theApplication of the method to synthetic mixtures of the

drug product componentsdrug product components

to which known quantitiesto which known quantities

of the analyteof the analyte

have been addedhave been added

RecoveryRecovery reducedreduced

byby ~10 15%~10 15%

From: Analytical Method Validation and Instrument Performance Verification, Edited byFrom: Analytical Method Validation and Instrument Performance Verification, Edited byChung Chow Chan,Herman Lam, Y.C. Lee and Xue-Ming Zhang, ISBN 0-471-25953-5, Wiley &Chung Chow Chan,Herman Lam, Y.C. Lee and Xue-Ming Zhang, ISBN 0-471-25953-5, Wiley &SonsSons


27/51


28/51



SpecificitySpecificity Is the ability to assess unequivocally the analyte in the presence of componentsIs the ability to assess unequivocally the analyte in the presence of components

which may be expected to be present (impurities, degradants, matrix)which may be expected to be present (impurities, degradants, matrix)

Identity testingIdentity testing

To ensure the identity of an analyteTo ensure the identity of an analyte

Purity testingPurity testing

To ensure accurate statement on the content of impurities of an analyteTo ensure accurate statement on the content of impurities of an analyte

AssayAssay

To allow an accurate statement on the content of an analyte in a sampleTo allow an accurate statement on the content of an analyte in a sample


29/51



Specificity:Specificity:Overlay chromatogram of an impurity solution with aOverlay chromatogram of an impurity solution with asample solutionsample solution



30/51



Specificity andSpecificity and stabilitystability Stress stability testing to ensure theStress stability testing to ensure the stability indicating potentialstability indicating potential of anof an

analytical methodanalytical method Apply diverse stress factors to the APIApply diverse stress factors to the API

Apply diverse stress factors to the FPPApply diverse stress factors to the FPP

Stress conditions: e.g. Supplement 2 of Generic Guideline;Stress conditions: e.g. Supplement 2 of Generic Guideline;TRS 929, Annex 5TRS 929, Annex 5

Assure that the API can be assessed specifically in the presence ofAssure that the API can be assessed specifically in the presence ofknown and unknown (generated by stress) impuritiesknown and unknown (generated by stress) impurities

Assure that known impurities/degradants can be specifically assessedAssure that known impurities/degradants can be specifically assessedin the presence of further degradantsin the presence of further degradants

ByBy peak purity assessmentpeak purity assessment and (overlay of)and (overlay of) chromatogramschromatograms


31/51



StressStress stability studies versusstability studies versus forced degradationforced degradation studiesstudiesStressStress

parameterparameterForced degradationForced degradation Stress stabilityStress stability

(5 15% decomposition)(5 15% decomposition)

AcidAcid 0.2 ml0.2 ml 1N HCl1N HCl / 5 ml API-solution / 3h,/ 5 ml API-solution / 3h,6h, 12h, 24h7d (RT & 60C)6h, 12h, 24h7d (RT & 60C)

pHpH 2 (2 weeks) 2 (2 weeks)

BaseBase 0.2 ml0.2 ml 1N NaOH1N NaOH / 5 ml API-solution // 5 ml API-solution /3h, 6h, 12h, 24h7d (RT & 60C)3h, 6h, 12h, 24h7d (RT & 60C)

pHpH 10 (2 weeks) 10 (2 weeks)

HH22OO22 / Oxygen/ Oxygen 0.2 ml 5% or0.2 ml 5% or35%35% HH22OO22/ 5 ml API-/ 5 ml API-

solution (RT, to 7d & 60C, 3h)solution (RT, to 7d & 60C, 3h)

1 g/ml oxygen bubbled through (8 hours)1 g/ml oxygen bubbled through (8 hours)0.1 2% H0.1 2% H22OO22 (24 hours)(24 hours)

HeatHeat 60C60C / 5 ml solution (3h, 6h7d)/ 5 ml solution (3h, 6h7d) --

HeatHeat 105 C105 C / solid API (1d and 7d)/ solid API (1d and 7d) 60C (4 weeks)60C (4 weeks)

UV or LightUV or Light 365 nm or white fluorescent light / solid365 nm or white fluorescent light / solidAPI (1d and 7d)API (1d and 7d)

HumidityHumidity -- 50C / 80% RH (4 weeks)50C / 80% RH (4 weeks)


32/51



Limit of Detection (LOD, DL)Limit of Detection (LOD, DL) The LOD of an analytical procedure is the lowest amount of analyte in sampleThe LOD of an analytical procedure is the lowest amount of analyte in sample

which can bewhich can be detected but not necessarily quantitated as an exact valuedetected but not necessarily quantitated as an exact value

Determination is usually based onDetermination is usually based on

Signal to noise ratio (~3:1) (Signal to noise ratio (~3:1) (baseline noisebaseline noise))oror

Standard deviation of response (Standard deviation of response () and Slope (S)) and Slope (S)

3.33.3 /S/S


33/51



Limit of Quantitation (LOQ, QL)Limit of Quantitation (LOQ, QL) The LOQ is the lowest amount of analyte in a sample which can beThe LOQ is the lowest amount of analyte in a sample which can be

quantitativelyquantitatively determined with suitable precision and accuracydetermined with suitable precision and accuracy

The quantitation limit is used particularly for theThe quantitation limit is used particularly for thedetermination of impurities and/or degradationdetermination of impurities and/or degradation

productsproducts

Determination is usually based onDetermination is usually based on

Signal to noise ratio (~10:1) (Signal to noise ratio (~10:1) (baseline noisebaseline noise))

oror Standard deviation of response (Standard deviation of response () and Slope (S)) and Slope (S)

1010 //SS


34/51



NoiseNoise

LODLODSignal toSignal to NoiseNoise = 3:= 3:11

LOQLOQ

Signal toSignal to NoiseNoise = 10:= 10:11

LOD, LOQ and Signal to Noise Ratio (SNRLOD, LOQ and Signal to Noise Ratio (SNR))


35/51



LOQLOQ Quantitation by SNR is acceptedQuantitation by SNR is accepted

Quantitation by Standard deviation of response (Quantitation by Standard deviation of response () and Slope (S)) and Slope (S)

(10(10 //S) is more adequate as it involves theS) is more adequate as it involves the responseresponse of the actualof the actual

analyteanalyte

Best to calculate in the region close to y-interceptBest to calculate in the region close to y-intercept


36/51



LOQ and impuritiesLOQ and impurities

In determination of impurities in APIs and FPPs the LOQ should beIn determination of impurities in APIs and FPPs the LOQ should be

determineddetermined in the presence of APIin the presence of API

LOQ should beLOQ should be NMT reporting levelNMT reporting level

LOQ should be givenLOQ should be given relativerelative to the test concentrationto the test concentrationof APIof API

Specificity of impurity determination should always be demonstratedSpecificity of impurity determination should always be demonstrated

in the presence of APIin the presence of API at API specification levelsat API specification levels

Spiking of test concentration (API/FPP) with impurities atSpiking of test concentration (API/FPP) with impurities atlevels of their specification rangelevels of their specification range


37/51



SpikingSpiking API test concentration (normalised)API test concentration (normalised)

0.1 mg/ml (100%)0.1 mg/ml (100%)

Impurity spiking concentrationsImpurity spiking concentrations

0.001 mg/ml (1%) specification limit0.001 mg/ml (1%) specification limit 0.0001 mg/ml (0.1%)0.0001 mg/ml (0.1%) limit of quantitation limit of quantitation(minimum requirement)(minimum requirement)

API at test concentrationsAPI at test concentrations

API below test concentrationsAPI below test concentrations


38/51



LinearityLinearityof an analytical procedure is its ability (of an analytical procedure is its ability (within a givenwithin a given rangerange))to obtain testto obtain test resultsresultswhich are directlywhich are directly proportional to theproportional to the

concentrationconcentration (amount) of analyte in the sample(amount) of analyte in the sample

If there is aIf there is a linearlinearrelationshiprelationship test results should be evaluatedtest results should be evaluatedby appropriateby appropriate statistical methodsstatistical methods

Correlation coefficient (r)Correlation coefficient (r)

Y-interceptY-intercept

Slope of regression lineSlope of regression line

Residual sum of squaresResidual sum of squares

PLOT OF THE DATAPLOT OF THE DATA


39/51



Usual acceptance criteria for a linear calibrationUsual acceptance criteria for a linear calibrationcurvecurve r > 0.999r > 0.999;; y-intercept a < 0 to 5% of target concentrationy-intercept a < 0 to 5% of target concentration

RSD (wrt calibration curve) < 1.5-2%RSD (wrt calibration curve) < 1.5-2%

r > 0.997 r < 0.997

From: Analytical Method Validation and Instrument Performance Verification, Edited by Chung ChowFrom: Analytical Method Validation and Instrument Performance Verification, Edited by Chung ChowChan,Herman Lam, Y.C. Lee andChan,Herman Lam, Y.C. Lee andXue-Ming Zhang, ISBN 0-471-25953-5, Wiley & SonsXue-Ming Zhang, ISBN 0-471-25953-5, Wiley & Sons


40/51



RangeRange

TheThe rangerange of an analytical procedure is the intervalof an analytical procedure is the interval

between the upper and lower concentration (amounts) ofbetween the upper and lower concentration (amounts) of

analyte in the sample for which it has been demonstratedanalyte in the sample for which it has been demonstrated

that the analytical procedure has athat the analytical procedure has a suitable level ofsuitable level of

precision, accuracy and linearityprecision, accuracy and linearity


41/51



RangeRange AssayAssay 80 to 120%80 to 120% of test concentrationof test concentration

Content uniformityContent uniformity

70 to 130%70 to 130% of test concentrationof test concentration

DissolutionDissolution Q-20% to 120%Q-20% to 120%

ImpuritiesImpurities

Reporting level 120% of specification limit (with respect toReporting level 120% of specification limit (with respect totest concentration of API)test concentration of API)

Assay & ImpuritiesAssay & Impurities

Reporting level to 120% of assay specificationReporting level to 120% of assay specification


42/51



Linearity is limited to 150%of shelf life specification of impuritiesLinearity is limited to 150%of shelf life specification of impurities

Test concentration can beTest concentration can be

used to determine impuritiesused to determine impurities

To determine drug substanceTo determine drug substance(assay) the test concentration(assay) the test concentration

must be dilutedmust be diluted

The range is 0 ~ 150% ofThe range is 0 ~ 150% of

impurity specificationimpurity specification



43/51



RobustnessRobustness Robustness of an analytical procedure should showRobustness of an analytical procedure should show

thethe reliabilityreliability of an analysisof an analysis with respect towith respect to deliberatedeliberatevariations in method parametersvariations in method parameters

The evaluation of robustness should be consideredThe evaluation of robustness should be consideredduring theduring the development phasedevelopment phase

If measurements areIf measurements are susceptiblesusceptible to variations into variations inanalytical conditions theanalytical conditions the analytical conditions shouldanalytical conditions shouldbe suitably controlledbe suitably controlled or aor a precautionary statementprecautionary statementshould be included in the procedureshould be included in the procedure


44/51



Influence of buffer pH and buffer concentration in mobile phase onInfluence of buffer pH and buffer concentration in mobile phase onretention times of API and impuritiesretention times of API and impurities

Conclusion: The buffer composition should be maintained in a range ofConclusion: The buffer composition should be maintained in a range of

8585 0.5% 0.5% Missing:Missing: Acceptance criterion for maximal deviation of retention time should beAcceptance criterion for maximal deviation of retention time should be

defined unless justifieddefined unless justified

APIAPI Impurity AImpurity A Impurity BImpurity B Impurity CImpurity C

As isAs is 10.4610.46 3.863.86 7.437.43 8.268.26

buffer pH 5.9buffer pH 5.9 10.4510.45 3.943.94 7.517.51 8.388.38

buffer pH 6.9buffer pH 6.9 10.4610.46 3.943.94 7.497.49 8.348.34

Buffer conc. 83%Buffer conc. 83% 7.847.84 3.433.43 6.166.16 6.666.66

Buffer conc. 87%Buffer conc. 87% 15.2615.26 4.774.77 9.619.61 11.1811.18


45/51



System suitability testingSystem suitability testing

Based on the concept that equipment, electronics,Based on the concept that equipment, electronics,

analytical operations and samples to be analysedanalytical operations and samples to be analysed

constitute an integral systemconstitute an integral system that can be evaluated asthat can be evaluated as

suchsuch

Suitability parameters are established for each analyticalSuitability parameters are established for each analytical

procedureprocedureindividuallyindividually

Depend on theDepend on the type of analytical proceduretype of analytical procedure


46/51



MethodMethod stabilitystability System suitabilitySystem suitability over timeover time

Sample solution stabilitySample solution stability A solution of stavudine is stable for ~ 2 h, then it starts to degradeA solution of stavudine is stable for ~ 2 h, then it starts to degrade

to thymineto thymine

Impurity-spiked sample solution stabilityImpurity-spiked sample solution stabilityA solution containing stavudine spiked with its impurityA solution containing stavudine spiked with its impurity

thyminethyminedoes not allow to clearly distinguish betweendoes not allow to clearly distinguish betweendegradation and spikedegradation and spikeA solution containing stavudine of a FPP-stability sampleA solution containing stavudine of a FPP-stability sample

solution does not allow to clearly distinguish between FPP-solution does not allow to clearly distinguish between FPP-stability degradation and sample solution degradationstability degradation and sample solution degradation

Should be analysed immediatelyShould be analysed immediately


47/51



When to be surprised about validation data:When to be surprised about validation data:

Precision ofPrecision of

impurity determinationimpurity determination

Precision ofPrecision ofAPI determinationAPI determination

Method precision ofMethod precision of

released API (dissolution)released API (dissolution)

System precisionSystem precision % RSD 0.33 2.25% RSD 0.33 2.25

Method precisionMethod precision % RSD 0.0% RSD 0.0

Average peak areaAverage peak area % RSD 0.08% RSD 0.08

Acceptance criterionAcceptance criterion % RSD 2.0% RSD 2.0

Average peak areaAverage peak area % RSD 0.4% RSD 0.4

Acceptance criterionAcceptance criterion % RSD 10.0% RSD 10.0


48/51



Specification range (USL-LSL)Specification range (USL-LSL) Process variability (usuallyProcess variability (usually 2 SD) 2 SD)

Analytical variability (Analytical variability ( 3 3)) ~ NMT 30% of total specification range~ NMT 30% of total specification range

Analytical variabilityAnalytical variability Process variabilityProcess variability

Reliability of evaluation of major process variablesReliability of evaluation of major process variables by analyticalby analyticalproceduresprocedures depends ondepends on analytical variabilityanalytical variability

ImpuritiesImpurities

LOQLOQ and specification limit (e.g. qualification limits NMTand specification limit (e.g. qualification limits NMT0.15%)0.15%)

Response factorsResponse factors (LOQ modified by response factor)(LOQ modified by response factor)


49/51



Methods for cleaning validationMethods for cleaning validation Method for assay and related substances used in stability studies of APIMethod for assay and related substances used in stability studies of API

and FPPand FPP

SpecificitySpecificity (in(in samples taken from a cleaning assessmentsamples taken from a cleaning assessment))

LLinearity of responseinearity of response (from(from 50% of the cleaning limit to50% of the cleaning limit to 110x this0x this

concentrationconcentration; R; R

22

0.9900)0.9900) PrecisionPrecision

RepeatabilityRepeatability (RSD(RSD 5%)5%)

iinterntermediate precision [ruggedness (USP)]mediate precision [ruggedness (USP)]

ReproducibilityReproducibility

LLimits of detection and quantitationimits of detection and quantitation

AAccuracy or recovery from rinsateccuracy or recovery from rinsate (( 80%)80%), swabs, swabs (( 90%)90%), and, andprocess surfaceprocess surface (( 70%)70%)

RRangeange ((lowest level is at least 2x higher thanlowest level is at least 2x higher than LOQLOQ))


50/51



SummarySummary Analytical procedures play a critical role in pharmaceuticalAnalytical procedures play a critical role in pharmaceutical

equivalence and risk assessment/managementequivalence and risk assessment/management

Establishment ofEstablishment ofproduct-specificproduct-specific acceptance criteriaacceptance criteria

Assessment ofAssessment ofstabilitystability of APIs and FPPsof APIs and FPPs

Validation of analytical procedures should demonstrate thatValidation of analytical procedures should demonstrate that

they arethey are suitable for their intended usesuitable for their intended use

Validation of analytical procedures deservesValidation of analytical procedures deserves special attentionspecial attentionduring assessmentduring assessment of dossiersof dossiers for prequalificationfor prequalification


51/51


THANK YOUTHANK YOU

Analy Meth Dev

Documents